Research Article Details
| Article ID: | A19140 |
| PMID: | 26732004 |
| Source: | Clin Lab |
| Title: | The Higher Prevalence of Non-Alcoholic versus Alcoholic Steatohepatitis in Alcoholics. |
| Abstract: | BACKGROUND: The aim of this study was to evaluate the prevalence of alcoholic (ASH) and non-alcoholic steatohepatitis (NASH) in alcoholics by non-invasive biochemical markers: AshTest and NashTest. METHODS: The tested group consisted of 142 alcoholic patients. All biochemical markers were assessed using the recommended methods. RESULTS: The highest values of AshTest and NashTest were observed in the highest H3 score and N2 score, respectively. The distribution of AshTest scores was the following: H0 - 94.1%, H1 - 5.2%, H2 - 0%, and H3 - 0.7%, while for NashTest was: N0 - 56.6%, N1 - 38.2% and N2 - 5.1%. In summary, alcoholic steatohepatitis was present only in 5.9% of alcoholics and non-alcoholic steatohepatitis in 43.3% of patients. Co-occurrence of ASH and NASH was observed in 3.7% of patients. The BMI, mean glucose, and triglyceride levels were significantly different between NashTest scores, but not between AshTest scores. These results may evidence that non-alcoholic steatohepatitis is associated with metabolic risk factors such as diabetes mellitus, dyslipidemia, and obesity. The MCV value and AST/ALT ratio were higher in alcoholic steatohepatitis than in non-alcoholic steatohepatitis. CONCLUSIONS: In conclusion, the prevalence of non-alcoholic steatohepatitis in alcoholics is higher than of alcoholic steatohepatitis, as estimated by non-invasive tests. Co-occurrence of alcoholic steatohepatitis and non-alcoholic steatohepatitis in alcoholic patients is low and the high prevalence of non-alcoholic steatohepatitis is related with high occurrence of metabolic risk factors. |
| DOI: | 10.7754/clin.lab.2015.150434 |
| Strategy ID | Therapy Strategy | Synonyms | Therapy Targets | Therapy Drugs |
|---|
| Target ID | Target Name | GENE | Action | Class | UniProtKB ID | Entry Name |
|---|
| Diseases ID | DO ID | Disease Name | Definition | Class | |
|---|---|---|---|---|---|
| I13 | 3146 | Lipid metabolism disorder | An inherited metabolic disorder that involves the creation and degradation of lipids. http://en.wikipedia.org/wiki/Lipid_metabolism | disease of metabolism/ inherited metabolic disorder | Details |
| I05 | 9352 | Type 2 diabetes mellitus | A diabetes that is characterized by chronic hyperglycaemia with disturbances of carbohydrate, fat and protein metabolism resulting from defects in insulin secretion, insulin action, or both. A diabetes mellitus that is characterized by high blood sugar, insulin resistance, and relative lack of insulin. http://en.wikipedia.org/wiki/Diabetes, http://en.wikipedia.org/wiki/Diabetes_mellitus_type_2 | disease of metabolism/inherited metabolic disorder/ carbohydrate metabolic disorder/glucose metabolism disease/diabetes/ diabetes mellitus | Details |
| I14 | 9970 | Obesity | An overnutrition that is characterized by excess body fat, traditionally defined as an elevated ratio of weight to height (specifically 30 kilograms per meter squared), has_material_basis_in a multifactorial etiology related to excess nutrition intake, decreased caloric utilization, and genetic susceptibility, and possibly medications and certain disorders of metabolism, endocrine function, and mental illness. https://en.wikipedia.org/wiki/Obesity | disease of metabolism/acquired metabolic disease/ nutrition disease/overnutrition | Details |
| Drug ID | Drug Name | Type | DrugBank ID | Targets | Category | Latest Progress | |
|---|---|---|---|---|---|---|---|
| D328 | Serine | Chemical drug | DB00133 | SRR | Improve insulin resistance | Under clinical trials | Details |
| D094 | Cysteamine | Chemical drug | DB00847 | GSS stimulant | Renal drug | Under clinical trials | Details |
| D095 | Cysteamine bitartrate | Chemical drug | DB00847 | -- | -- | Under clinical trials | Details |